Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-09-13, Stock:NVS, The news for the past five days is as follows:
2019-09-06: NEWS1: Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?.NEWS2: FDA Grants Priority Review to Global Blood's SCD Candidate.NEWS3: Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA.NEWS4: Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs.NEWS5: UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful.NEWS6: 4 Biotech Stocks With Big Catalysts in September.NEWS7: 4 Biotech Stocks With Big Catalysts in September.
2019-09-09: NEWS1: Amarin: Keep Your Dry Powder Ready.NEWS2: Amarin: Keep Your Dry Powder Ready.NEWS3: This Rockville biotech has added another deal to its growth plan.NEWS4: Novartis Announces Positive Long-Term Data on Migraine Drug.NEWS5: UPDATE 1-Novartis CEO promises to speed data integrity disclosures.NEWS6: Novartis CEO pledges to speed data integrity disclosures.
2019-09-10: NEWS1: NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  – NVS.
2019-09-11: NEWS1: Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS).NEWS2: Leaner Pfizer Positioned to Boost R&D Output.NEWS3: Pharma Stock Calls Could Double Fast.NEWS4: INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS).NEWS5: Why Amgen Stock Perked Up Last Month.NEWS6: Why Amgen Stock Perked Up Last Month.NEWS7: 4 Big Drugmakers Boasting Impressive Oncology Pipelines.NEWS8: ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS9: Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe.NEWS10: Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe.NEWS11: Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe.
2019-09-12: NEWS1: Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance.NEWS2: Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance.NEWS3: J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients.NEWS4: J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients.NEWS5: Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance.NEWS6: J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients.NEWS7: Has Novartis (NVS) Outpaced Other Medical Stocks This Year?.

Answer: Decrease